NanoViricides, Inc. (NYSE American: NNVC) highlighted the potential need for broad-spectrum antiviral treatments following the recent Andes hantavirus incident aboard a cruise ship, pointing to its clinical-stage antiviral candidate NV-387 as a potential therapeutic platform for emerging viral threats. The company said NV-387 has completed a Phase I safety and tolerability trial in healthy volunteers and has demonstrated effectiveness in animal models involving multiple viral lung infections, including coronaviruses, RSV, influenza, monkeypox and measles, as it advances development of a platform designed to target a broad range of pathogenic viral infections.
The Andes hantavirus, which is typically found in South America, can cause hantavirus pulmonary syndrome, a severe respiratory disease. The incident on a cruise ship underscores the risk of emerging viral diseases and the importance of having broad-spectrum antivirals available. NV-387, a novel broad-spectrum antiviral drug candidate, is designed to target a wide range of viruses, including those that cause respiratory infections. According to the company, NV-387 has shown efficacy in animal models against not only coronaviruses and influenza but also monkeypox, smallpox, and measles, indicating its potential as a versatile therapeutic.
NanoViricides is a clinical-stage company that creates special purpose nanomaterials for antiviral therapy. NV-387 is the company's lead drug candidate, and it is being developed as a treatment for RSV, COVID-19, Long COVID, influenza, and other respiratory viral infections. The successful completion of a Phase I clinical trial in healthy volunteers with no reported adverse events is a significant milestone, and the company is now focused on advancing NV-387 into Phase II human clinical trials.
The company's other advanced drug candidate is NV-HHV-1, aimed at treating all herpesvirus infections, including HSV-1, HSV-2, VZV shingles, and chickenpox. However, the company cannot project an exact date for filing an Investigational New Drug (IND) application for any of its drugs due to dependence on external collaborators and consultants.
The recent Andes hantavirus incident serves as a reminder of the constant threat posed by emerging viruses and the need for effective antiviral treatments. NanoViricides' broad-spectrum approach could be crucial in addressing such threats. For more information, visit NanoViricides or view the full press release at https://ibn.fm/OYkof.
